DME

Amid conflicting findings, factors such as dosage, patient characteristics may affect outcomes.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

Today, Alimera Sciences announced that they have acquired the US commercial rights of Yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis. Yutiq now joins Iluvien (fluocinolone acetonide intravitreal insert) 0.19 mg for DME in Alimera’s retina portfolio.

New research identifies potential new TED biomarkers based on the disease activity or inactivity.

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.

Case history can give clues to a patient’s risk of developing diabetic eye disease.

The ERG is a game changer for patients with diabetes.

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all tertiles.

OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone that has the potential to be the first topical eye drop and non-invasive treatment for DME.

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

New DME treatments aim to extend time between intravitreal injections.

A recent clinical trial from the DRCR Retina Network examined a stepped regimen of anti-VEGF drugs bevacizumab and aflibercept.

IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

Proper screenings, treatment, management needed for this increasingly prevalent disease.

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

Advancements enable better diagnosis, treatment of patients.

A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.

All data were collected in the Fight Retinal Blindness! Registry.

This is the second FDA-approved indication for BEOVU; it was initially approved in 2019 for the treatment of wet AMD.

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.

Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.